FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 313:7-11 July 4, 1985 Number 1 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Multiple neurotransmitter deficits found in recent autopsy studies of patients with Alzheimer's disease may militate against the success of "simple cholinergic replacement" as treatment. To study acetylcholine synthesis, we measured the incorporation of radiolabeled glucose into the transmitter in temporal-cortex specimens obtained at diagnostic craniotomy in 17 young patients with Alzheimer's disease. Synthesis of acetylcholine was significantly correlated with cognitive impairment. These results are consistent with the view that the deficit in the presynaptic cholinergic system is a relatively early change in the development of the clinical features of the disease. Other alterations in noradrenergic cells, some cortical neurons, postsynaptic cortical receptors, and possibly serotoninergic cells may not be closely associated with Alzheimer's disease.

This article has been cited by other articles:

• Thathiah, A., De Strooper, B. (2009). G Protein-Coupled Receptors, Cholinergic Dysfunction, and A{beta} Toxicity in Alzheimer's Disease. Sci Signal 2: re8-re8 [Abstract] [Full Text]  
• Sunderland, T., Hampel, H., Takeda, M., Putnam, K. T., Cohen, R. M. (2006). Biomarkers in the Diagnosis of Alzheimer's Disease: Are We Ready?. J Geriatr Psychiatry Neurol 19: 172-179 [Abstract]  
• Claassen, J. A. H. R., Jansen, R. W. M. M. (2006). Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61: 267-271 [Abstract] [Full Text]  
• Aracava, Y., Pereira, E. F. R., Maelicke, A., Albuquerque, E. X. (2005). Response: Comments on "Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons". J. Pharmacol. Exp. Ther. 313: 930-933 [Full Text]  
• Aracava, Y., Pereira, E. F. R., Maelicke, A., Albuquerque, E. X. (2005). Memantine Blocks {alpha}7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons. J. Pharmacol. Exp. Ther. 312: 1195-1205 [Abstract] [Full Text]  
• Herrmann, N., Lanctot, K. L., Khan, L. R. (2004). The Role of Norepinephrine in the Behavioral and Psychological Symptoms of Dementia. J. Neuropsychiatry Clin. Neurosi. 16: 261-276 [Abstract] [Full Text]  
• Mesulam, M. (2004). The Cholinergic Lesion of Alzheimer's Disease: Pivotal Factor or Side Show?. Learn. Mem. 11: 43-49 [Abstract] [Full Text]  
• P. Lai, M. K., Lai, O. -F., Keene, J., Esiri, M. M., Francis, P. T., Hope, T., Chen, C. P.L.-H. (2001). Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 57: 805-811 [Abstract] [Full Text]  
• Lanctôt, K. L., Herrmann, N., Mazzotta, P. (2001). Role of Serotonin in the Behavioral and Psychological Symptoms of Dementia. J. Neuropsychiatry Clin. Neurosi. 13: 5-21 [Abstract] [Full Text]  
• Minger, S. L., Esiri, M. M., McDonald, B., Keene, J., Carter, J., Hope, T., Francis, P. T. (2000). Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55: 1460-1467 [Abstract] [Full Text]  
• Dronfield, S., Egan, K., Marsden, C. A., Green, A. R. (2000). Comparison of donepezil-, tacrine-, rivastigmine-and metrifonateinduced central and peripheral cholinergically mediated responses in the rat. J Psychopharmacol 14: 275-279 [Abstract]  
• Corey-Bloom, J., Tiraboschi, P., Hansen, L. A., Alford, M., Schoos, B., Sabbagh, M. N., Masliah, E., Thal, L. J. (2000). E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology 54: 403-403 [Abstract] [Full Text]  
• Winkler, J., Ramirez, G. A., Thal, L. J., Waite, J. J. (2000). Nerve Growth Factor (NGF) Augments Cortical and Hippocampal Cholinergic Functioning after p75NGF Receptor-Mediated Deafferentation But Impairs Inhibitory Avoidance and Induces Fear-Related Behaviors. J. Neurosci. 20: 834-844 [Abstract] [Full Text]  
• Sabbagh, M. N., Corey-Bloom, J., Tiraboschi, P., Thomas, R., Masliah, E., Thal, L. J. (1999). Neurochemical Markers Do Not Correlate With Cognitive Decline in the Lewy Body Variant of Alzheimer Disease. Arch Neurol 56: 1458-1461 [Abstract] [Full Text]  
• Thal, L. J., Ferguson, J. M., Mintzer, J., Raskin, A., Targum, S. D. (1999). A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 52: 1146-1146 [Abstract] [Full Text]  
• Felician, O., Sandson, T. A. (1999). The Neurobiology and Pharmacotherapy of Alzheimer's Disease. J. Neuropsychiatry Clin. Neurosi. 11: 19-31 [Abstract] [Full Text]  
• Nuwer, M. (1997). Assessment of digital EEG, quantitative EEG, and EEG brain mapping: Report of the American Academy of Neurology and the American Clinical Neurophysiology Society. Neurology 49: 277-292 [Full Text]  
• Koller, W. C., Montgomery, E. B. (1997). Issues in the early diagnosis of Parkinson's disease. Neurology 49: S10-S25 [Abstract] [Full Text]  
• Litvan, I., Agid, Y., Goetz, C., Jankovic, J., Wenning, G. K., Brandel, J. P., Lai, E. C., Verny, M., Ray-Chaudhuri, K., McKee, A., Jellinger, K., Pearce, R.K.B., Bartko, J. J. (1997). Accuracy of the Clinical Diagnosis of Corticobasal Degeneration: A Clinicopathologic Study. Neurology 48: 119-125 [Abstract] [Full Text]  
• Cummings, J. L., Kaufer, D. (1996). Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 47: 876-883 [Abstract] [Full Text]  
• de Villemeur, T. B., Deslys, J-P., Pradel, A., Soubrie, C., Alperovitch, A., Tardieu, M., Chaussain, J-L., Hauw, J-J., Dormont, D., Ruberg, M., Agid, Y. (1996). Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology 47: 690-695 [Abstract] [Full Text]  
• Wientjens, D. P.W.M., Davanipour, Z., Hofman, A., Kondo, K., Matthews, W. B., Will, R. G., van Duijn, C. M. (1996). Risk factors for Creutzfeldt-Jakob disease: A reanalysis of case-control studies. Neurology 46: 1287-1287 [Abstract] [Full Text]  
• Samuel, W., Terry, R. D., DeTeresa, R., Butters, N., Masliah, E. (1994). Clinical Correlates of Cortical and Nucleus Basalis Pathology in Alzheimer Dementia. Arch Neurol 51: 772-778 [Abstract]  
• Du, W., DiLuca, C., Growdon, J. H. (1993). Weight Loss in Alzheimer's Disease. J Geriatr Psychiatry Neurol 6: 34-38 [Abstract]  
• (1993). Tacrine for Alzheimer's Disease: A More Definitive Report. J Geriatr Psychiatry Neurol 6: 59-60  
• Weinberger, D. R., Gibson, R., Coppola, R., Jones, D. W., Molchan, S., Sunderland, T., Berman, K. F., Reba, R. C. (1991). The Distribution of Cerebral Muscarinic Acetylcholine Receptors In Vivo in Patients With Dementia: A Controlled Study With 123IQNB and Single Photon Emission Computed Tomography. Arch Neurol 48: 169-176 [Abstract]  
• Read, S. L., Frazee, J., Shapira, J., Smith, C., Cummings, J. L., Tomiyasu, U. (1990). Intracerebroventricular Bethanechol for Alzheimer's Disease: Variable Dose-Related Responses. Arch Neurol 47: 1025-1030 [Abstract]  
• Jenike, M. A., Albert, M., Baer, L., Gunther, J. (1990). Oral Physostigmine as Treatment for Primary Degenerative Dementia: A Double-Blind Placebo-Controlled Inpatient Trial. J Geriatr Psychiatry Neurol 3: 13-16 [Abstract]  
• Small, G. W., Kuhl, D. E., Riege, W. H., Fujikawa, D. G., Ashford, J. W., Metter, E. J., Mazziotta, J. C. (1989). Cerebral Glucose Metabolic Patterns in Alzheimer's Disease: Effect of Gender and Age at Dementia Onset. Arch Gen Psychiatry 46: 527-532 [Abstract]  
• Raskind, M. A., Peskind, E. R., Veith, R. C., Risse, S. C., Lampe, T. H., Borson, S., Gumbrecht, G., Dorsa, D. M. (1989). Neuroendocrine Responses to Physostigmine in Alzheimer's Disease. Arch Gen Psychiatry 46: 535-540 [Abstract]  
• Crino, P. B., Ullman, M. D., Vogt, B. A., Bird, E. D., Volicer, L. (1989). Brain Gangliosides in Dementia of the Alzheimer Type. Arch Neurol 46: 398-401 [Abstract]  
• Vinters, H. V., Miller, B. L., Pardridge, W. M. (1988). Brain Amyloid and Alzheimer Disease. ANN INTERN MED 109: 41-54 [Abstract]  
• Bondareff, W., Mountjoy, C. Q., Roth, M., Rossor, M. N., Iversen, L. L., Reynolds, G. P. (1987). Age and Histopathologic Heterogeneity in Alzheimer's Disease: Evidence for Subtypes. Arch Gen Psychiatry 44: 412-417 [Abstract]  
• Tariot, P. N., Cohen, R. M., Sunderland, T., Newhouse, P. A., Yount, D., Mellow, A. M., Weingartner, H., Mueller, E. A., Murphy, D. L. (1987). L-Deprenyl in Alzheimer's Disease: Preliminary Evidence for Behavioral Change With Monoamine Oxidase B Inhibition. Arch Gen Psychiatry 44: 427-433 [Abstract]  
• Marston, H.M., Martin, K.J., Robbins, T.W. (1987). Effects of the chronic administration of pyrithioxin on behaviour and cholinergic function in young and aged rats. J Psychopharmacol 1: 237-243 [Abstract]  
• Bruno, G., Mohr, E., Gillespie, M., Fedio, P., Chase, T. N. (1986). Muscarinic Agonist Therapy of Alzheimer's Disease: A Clinical Trial of RS-86. Arch Neurol 43: 659-661 [Abstract]  
• Schweber, M. (1986). Etiologic theories of Alzheimer's disease. AM J ALZHEIMERS DIS OTHER DEMEN 1: 24-31 [Abstract]